Cantor Fitzgerald Predicts Nyxoah FY2025 Earnings

Nyxoah S.A. (NASDAQ:NYXH) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Nyxoah in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($2.22) for the year. Cantor Fitzgerald has a “Overweight” rating and a $16.00 price target on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.91) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Nyxoah in a research note on Friday, December 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $17.00.

Nyxoah Trading Up 4.2 %

NYXH opened at $10.81 on Thursday. The stock has a fifty day moving average of $8.70 and a 200-day moving average of $8.72. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. Nyxoah has a 12-month low of $6.76 and a 12-month high of $20.00.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.22). Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. The firm had revenue of $1.73 million for the quarter, compared to analyst estimates of $1.47 million. During the same quarter in the prior year, the firm earned ($0.29) EPS.

Institutional Trading of Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. CVI Holdings LLC purchased a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 183,590 shares of the company’s stock, valued at approximately $1,292,000. Nyxoah makes up 1.2% of CVI Holdings LLC’s investment portfolio, making the stock its 13th largest position. CVI Holdings LLC owned 0.74% of Nyxoah as of its most recent SEC filing.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.